BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Axsome Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Axsome Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06413433-866@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT06413433)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3.\nStudy: Elucidating TAAR-1\, D
 opamine\, and Norepinephrine in Binge Eating Disorder Using Solriamfetol\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/solriamfetol#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06413433
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568367-866@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT06568367)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3.\nStudy: Studying Solriamfetol 
 Modulation of TAAR-1\, Dopamine\, and Norepinephrine in Shift Work Disorde
 r (SUSTAIN)\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/solriamfetol#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06568367
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878976-866@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT06878976)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3.\nStudy: A Study to Assess the 
 Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eatin
 g Disorder\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/solriamfetol#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06878976
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773883-866@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07773883)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Attention Deficit Hyperactivi
 ty Disorder.\nStudy: An Open-Label Study to Assess the Long-Term Safety of
  Solriamfetol in Children and Adolescents With ADHD\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/solriamfetol#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07773883
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766655-667@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Auvelity (Dextromethorphan/bupropion): Phase 3 readout est. (NCT077
 66655)
DESCRIPTION:Auvelity (Dextromethorphan/bupropion)\, phase 3.\nStudy: Studyi
 ng NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)\nEstimated pri
 mary completion: December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dextromethorphan-bupropion#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07766655
URL:https://assetmemo.bio/drug/dextromethorphan-bupropion#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398417-10867@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Esreboxetine: Phase 3 readout est. (NCT07398417)
DESCRIPTION:Esreboxetine\, phase 3\, Fibromyalgia.\nStudy: Fibromyalgia Res
 ponse With Esreboxetine Evaluated Using a Randomized Withdrawal Research D
 esign\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/esreboxetine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07398417
URL:https://assetmemo.bio/drug/esreboxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637162-10867@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Esreboxetine: Phase 3 readout est. (NCT07637162)
DESCRIPTION:Esreboxetine\, phase 3\, Fibromyalgia.\nStudy: Open-Label Safet
 y Study of AXS-14 in Subjects With Fibromyalgia\nEstimated primary complet
 ion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/esrebo
 xetine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07637162
URL:https://assetmemo.bio/drug/esreboxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717879-866@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07717879)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Attention Deficit Hyperactivi
 ty Disorder.\nStudy: Forward Treatment of Attention Deficit and Hyperactiv
 ity Using Solriamfetol (FOCUS-2)\nEstimated primary completion: 30 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/solriamfetol#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07717879
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717892-866@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07717892)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Attention Deficit Hyperactivi
 ty Disorder.\nStudy: Forward Treatment of Attention Deficit and Hyperactiv
 ity Using Solriamfetol (FOCUS-3)\nEstimated primary completion: 30 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/solriamfetol#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07717892
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484217-866@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sunosi (Solriamfetol): Phase 3 readout est. (NCT07484217)
DESCRIPTION:Sunosi (Solriamfetol)\, phase 3\, Major Depressive Disorder.\nS
 tudy: Clinical Assessment of Response in the Treatment of Depression With 
 Daytime Sleepiness Using Solriamfetol\nEstimated primary completion: Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/solriamfeto
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 484217
URL:https://assetmemo.bio/drug/solriamfetol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
